Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 861 of 6351
-
Can talk therapy for sleep beat cancer fatigue?
Symptom relief OngoingCancer-related fatigue (CRF) and insomnia are prevalent among cancer patients and have been linked to de-creases in quality of life and poorer overall survivorship. Currently, the mechanisms underlying CRF are not well understood, which has led to treatments that are only moderat…
Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Symptom relief
Last updated Aug 23, 2026 00:00 UTC
-
New hope for never-smokers with advanced lung cancer: experimental drug combo enters phase 2 trial
Disease control Recruiting nowThe goal of this clinical trial is to determine clinical advantages for LP-300 in combination with carboplatin and pemetrexed in the never smoker patient population. The primary objectives of this study are to determine progression-free survival (PFS) and overall survival (OS) in…
Phase 2 • Sponsor: Lantern Pharma Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Could a common arthritis drug prevent preterm birth?
Prevention Recruiting nowThe goal of this randomized clinical trial is to assess sulfasalazine as a potential treatment to prevent recurrent preterm birth. The main questions it aims to answer are: * Does sulfasalazine down regulate corticotropin releasing hormone (CRH) levels in pregnant persons with a…
Phase 2 • Sponsor: Rutgers, The State University of New Jersey • Aim: Prevention
Last updated Jul 11, 2026 00:00 UTC
-
Could a melanoma drug combo tame rare BRAF cancers?
Disease control Recruiting nowThis clinical trial is looking at a combination of drugs called vemurafenib and cobimetinib. Vemurafenib is approved as standard of care for adult patients with unresectable or metastatic melanoma. Cobimetinib is approved as standard of care in combination with vemurafenib for th…
Phase 2/3 • Sponsor: Cancer Research UK • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
Could a party drug ease PTSD? new trial tests methylone
Symptom relief CompletedThis study is evaluating the safety, tolerability, and efficacy of methylone in adults with PTSD. The study will be conducted in two parts. * Part A is open-label and will enroll up to 15 participants with PTSD * Part B is randomized (1:1), double-blind, placebo-controlled and w…
Phase 1/2 • Sponsor: Transcend Therapeutics • Aim: Symptom relief
Last updated Jun 27, 2026 12:08 UTC
-
AI vs. experts: can machines master Parkinson's motor scoring?
Knowledge-focused CompletedThe Movement Disorders Society (MDS) Unified Parkinson's Disease Rating Scale (UPDRS) Part III (MDS-UPDRS III) is the primary assessment method for motor symptoms in Parkinson's disease patients. Currently, movement disorder specialists conduct semi-quantitative scoring, which en…
Sponsor: Ruijin Hospital • Aim: Knowledge-focused
Last updated Aug 23, 2026 00:00 UTC
-
Could a cancer therapy tame severe lupus? early trial launches
Disease control OngoingThe study is intended to assess safety, efficacy and cellular kinetics of YTB323 treatment in participants with severe refractory systemic lupus erythematosus.
Phase 1/2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
New dosing strategy aims to make Alzheimer's drug safer and more effective
Disease control OngoingThis study will investigate different donanemab dosing regimens and their effect on the frequency and severity of ARIA-E in adults with early symptomatic Alzheimer's disease (AD) and explore participant characteristics that might predict risk of ARIA. Approximately 375 additiona…
Phase 3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug ABC008 shows promise in slowing rare muscle disease
Disease control CompletedA Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Determine the Efficacy and Safety of ABC008 in the Treatment of Subjects with Inclusion Body Myositis
Phase 2/3 • Sponsor: Abcuro, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Molecular blueprint may unlock personalized liver cancer therapy
Knowledge-focused Recruiting nowHepatocellular carcinoma (HCC) is the 7th most common cancer worldwide but is the 4th deadliest, because diagnosis tend to be late and current systemic therapies are poorly efficacious. Within the same tumour, different parts of the HCC can belong to separate molecular sub-groups…
Phase 2 • Sponsor: National Cancer Centre, Singapore • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
New heart zapping device shows promise for stubborn AFib
Disease control CompletedThe objective of the ADVANTAGE AF Study is to establish the safety and effectiveness of the FARAPULSE Pulsed Field Ablation System (FARAPULSE PFA System) for treatment of drug resistant, symptomatic persistent atrial fibrillation (PersAF).
Sponsor: Boston Scientific Corporation • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Could a common diabetes drug curb weight gain in people with intellectual disabilities?
Disease control Recruiting nowPeople with IDD (intellectual and developmental disability) have very high rates of obesity and die prematurely from cardiometabolic disease. While antipsychotics contribute to this problem, their use is necessary and appropriate in a significant subgroup of individuals with IDD.…
Phase 4 • Sponsor: Centre for Addiction and Mental Health • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New immunotherapy shows promise for Tough-to-Treat colorectal cancer
Disease control OngoingThe main purpose of this study is to compare the clinical benefit, as measured by Progression-Free Survival (PFS), achieved by HX008 or Investigator's Choice Chemotherapy in participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) metastatic c…
Phase 3 • Sponsor: Taizhou Hanzhong biomedical co. LTD • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New oil therapy could slash Life-Threatening events in kids with rare metabolic disease
Disease control OngoingThe main goal of this study is to evaluate the effects of triheptanoin versus Medium-chain Triglycerides (MCT) on frequency of Major Clinical Events (MCEs).
Phase 3 • Sponsor: Ultragenyx Pharmaceutical Inc • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
New pulsed field ablation device aims to tame stubborn heart rhythm disorder
Disease control OngoingThe study evaluates the safety and effectiveness of the investigational QuickShot Nav configuration of the CardioWave System for focal catheter ablation of persistent atrial fibrillation (PerAF).
Sponsor: CardioFocus • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New mRNA inhalation therapy offers hope for Hard-to-Treat cystic fibrosis
Disease control OngoingThe purpose of this study is to evaluate the safety, and tolerability and efficacy of VX-522 in participants 18 years of age and older with cystic fibrosis and a cystic fibrosis transmembrane conductance regulator (CFTR) genotype not responsive to CFTR modulator therapy.
Phase 1/2 • Sponsor: Vertex Pharmaceuticals Incorporated • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Could a vaccine fight Alzheimer's? new trial begins
Vaccine OngoingPhase 1 clinical trial of AV-1959 amyloid-β vaccine for Alzheimer's disease (AD).
Phase 1 • Sponsor: Institute for Molecular Medicine • Aim: Vaccine
Last updated Jun 27, 2026 12:00 UTC
-
Blood test could detect hidden pancreatic tumors
Diagnosis Recruiting nowThis prospective study aims to evaluate the sensitivity and specificity of an integrated model using fragmentomic profiles of plasma cell-free DNA for early detection of pancreatic neuroendocrine tumors and differential diagnosis of solid pancreatic tumors.
Sponsor: Fudan University • Aim: Diagnosis
Last updated Jun 27, 2026 12:00 UTC
-
New combo aims to boost transplant success in Hodgkin's lymphoma
Disease control Recruiting nowThe phase I part (safety assessment of the combination treatment) is aimed at determining the MTD of atezolizumab when combined with BEGEV schedule. 6-18 patients enrolled in this part will be treated with atezolizumab in combination with BEGEV regimen every 3 weeks for 4 cycles…
Phase 1/2 • Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New hope for kids with severe hair loss: baricitinib pill tested in major trial
Disease control Recruiting nowThe main purpose of this study is to determine the efficacy and safety of baricitinib for the treatment of severe or very severe alopecia areata (hair loss) in children from 6 years to less than 18 years of age. The study is divided into 4 periods, a 5-week Screening period, a 3…
Phase 3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC